198 related articles for article (PubMed ID: 20654666)
41. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.
Pal R; Venzon D; Letvin NL; Santra S; Montefiori DC; Miller NR; Tryniszewska E; Lewis MG; VanCott TC; Hirsch V; Woodward R; Gibson A; Grace M; Dobratz E; Markham PD; Hel Z; Nacsa J; Klein M; Tartaglia J; Franchini G
J Virol; 2002 Jan; 76(1):292-302. PubMed ID: 11739694
[TBL] [Abstract][Full Text] [Related]
42. Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine.
Wang C; Jiang C; Gao N; Zhang K; Liu D; Wang W; Cong Z; Qin C; Ganusov VV; Ferrari G; LaBranche C; Montefiori DC; Kong W; Yu X; Gao F
Viruses; 2017 Jun; 9(6):. PubMed ID: 28574482
[TBL] [Abstract][Full Text] [Related]
43. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.
Clements JE; Montelaro RC; Zink MC; Amedee AM; Miller S; Trichel AM; Jagerski B; Hauer D; Martin LN; Bohm RP
J Virol; 1995 May; 69(5):2737-44. PubMed ID: 7707496
[TBL] [Abstract][Full Text] [Related]
44. Treatment with anti-FasL antibody preserves memory lymphocytes and virus-specific cellular immunity in macaques challenged with simian immunodeficiency virus.
Poonia B; Salvato MS; Yagita H; Maeda T; Okumura K; Pauza CD
Blood; 2009 Aug; 114(6):1196-204. PubMed ID: 19498020
[TBL] [Abstract][Full Text] [Related]
45. Control of Heterologous Simian Immunodeficiency Virus SIV
Singh S; Ramírez-Salazar EG; Doueiri R; Valentin A; Rosati M; Hu X; Keele BF; Shen X; Tomaras GD; Ferrari G; LaBranche C; Montefiori DC; Das J; Alter G; Trinh HV; Hamlin C; Rao M; Dayton F; Bear J; Chowdhury B; Alicea C; Lifson JD; Broderick KE; Sardesai NY; Sivananthan SJ; Fox CB; Reed SG; Venzon DJ; Hirsch VM; Pavlakis GN; Felber BK
J Virol; 2018 Aug; 92(15):. PubMed ID: 29793957
[TBL] [Abstract][Full Text] [Related]
46. Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination.
Enose Y; Kita M; Yamamoto T; Suzuki H; Miyake A; Horiuchi R; Ibuki K; Kaneyasu K; Kuwata T; Takahashi E; Sakai K; Shinohara K; Miura T; Hayami M
Arch Virol; 2004 Sep; 149(9):1705-20. PubMed ID: 15593414
[TBL] [Abstract][Full Text] [Related]
47. Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge.
Faul EJ; Aye PP; Papaneri AB; Pahar B; McGettigan JP; Schiro F; Chervoneva I; Montefiori DC; Lackner AA; Schnell MJ
Vaccine; 2009 Dec; 28(2):299-308. PubMed ID: 19879223
[TBL] [Abstract][Full Text] [Related]
48. Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.
Buge SL; Murty L; Arora K; Kalyanaraman VS; Markham PD; Richardson ES; Aldrich K; Patterson LJ; Miller CJ; Cheng SM; Robert-Guroff M
J Virol; 1999 Sep; 73(9):7430-40. PubMed ID: 10438833
[TBL] [Abstract][Full Text] [Related]
49. Relationship between Vaccine-Induced Antibody Capture of Infectious Virus and Infection Outcomes following Repeated Low-Dose Rectal Challenges with Simian Immunodeficiency Virus SIVmac251.
Gach JS; Venzon D; Vaccari M; Keele BF; Franchini G; Forthal DN
J Virol; 2016 Oct; 90(19):8487-95. PubMed ID: 27440881
[TBL] [Abstract][Full Text] [Related]
50. A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge.
Reynolds MR; Weiler AM; Piaskowski SM; Piatak M; Robertson HT; Allison DB; Bett AJ; Casimiro DR; Shiver JW; Wilson NA; Lifson JD; Koff WC; Watkins DI
Vaccine; 2012 Jun; 30(30):4465-75. PubMed ID: 22569124
[TBL] [Abstract][Full Text] [Related]
51. CD8 T Cells Show Protection against Highly Pathogenic Simian Immunodeficiency Virus (SIV) after Vaccination with SIV Gene-Expressing BCG Prime and Vaccinia Virus/Sendai Virus Vector Boosts.
Kato S; Shida H; Okamura T; Zhang X; Miura T; Mukai T; Inoue M; Shu T; Naruse TK; Kimura A; Yasutomi Y; Matsuo K
J Virol; 2021 Jan; 95(4):. PubMed ID: 33087465
[TBL] [Abstract][Full Text] [Related]
52. Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239.
Abel K; Rourke T; Lu D; Bost K; McChesney MB; Miller CJ
J Infect Dis; 2004 Nov; 190(9):1697-705. PubMed ID: 15478078
[TBL] [Abstract][Full Text] [Related]
53. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC
J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230
[TBL] [Abstract][Full Text] [Related]
54. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses.
Hel Z; Nacsa J; Tryniszewska E; Tsai WP; Parks RW; Montefiori DC; Felber BK; Tartaglia J; Pavlakis GN; Franchini G
J Immunol; 2002 Nov; 169(9):4778-87. PubMed ID: 12391187
[TBL] [Abstract][Full Text] [Related]
55. Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys.
Sun C; Chen Z; Tang X; Zhang Y; Feng L; Du Y; Xiao L; Liu L; Zhu W; Chen L; Zhang L
J Virol; 2013 May; 87(10):5669-77. PubMed ID: 23487457
[TBL] [Abstract][Full Text] [Related]
56. Immunogenicity of a DNA prime and recombinant adenovirus boost regime significantly varies between rhesus macaques of Chinese and Indian origins.
Stahl-Hennig C; Suh YS; Park KS; Sauermann U; Kim KS; Ahn S; Franz M; Schulte R; Stolte-Leeb N; Hunsmann G; Sung YC
J Med Primatol; 2007 Aug; 36(4-5):195-205. PubMed ID: 17669208
[TBL] [Abstract][Full Text] [Related]
57. Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines.
Israel ZR; Edmonson PF; Maul DH; O'Neil SP; Mossman SP; Thiriart C; Fabry L; Van Opstal O; Bruck C; Bex F
J Virol; 1994 Mar; 68(3):1843-53. PubMed ID: 8107246
[TBL] [Abstract][Full Text] [Related]
58. Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5).
Hulskotte EG; Geretti AM; Siebelink KH; van Amerongen G; Cranage MP; Rud EW; Norley SG; de Vries P; Osterhaus AD
J Virol; 1995 Oct; 69(10):6289-96. PubMed ID: 7666529
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of CD8+ T-cell and antibody responses following transient increased viraemia in rhesus macaques infected with live, attenuated simian immunodeficiency virus.
Metzner KJ; Moretto WJ; Donahoe SM; Jin X; Gettie A; Montefiori DC; Marx PA; Binley JM; Nixon DF; Connor RI
J Gen Virol; 2005 Dec; 86(Pt 12):3375-3384. PubMed ID: 16298985
[TBL] [Abstract][Full Text] [Related]
60. Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.
Mörner A; Jansson M; Bunnik EM; Schøller J; Vaughan R; Wang Y; Montefiori DC; Otting N; Bontrop R; Bergmeier LA; Singh M; Wyatt RT; Schuitemaker H; Biberfeld G; Thorstensson R; Lehner T
J Virol; 2011 Jul; 85(13):6442-52. PubMed ID: 21490092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
